Autoimmune diseases arise when the immune system mistakenly targets and damages the body’s cells and tissues as though they ...

A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

A mouse study suggests estrogen may increase gut pain by activating specific cells, offering hints to why IBS is more common ...

Study suggests CD4+ T cells mediate these immune-related toxicities ...

A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...

ImmunityBio’s stock rose nearly 40% after it announced the Phase I data and Anktiva sales figures for 2025.

Results from two clinical trials on ianalumab for Sjögren disease show favorable safety and adverse event outcomes, ...

Novartis has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ...

Jade Biosciences, Inc. ( JBIO) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 2:15 PM EST ...

Scientists are searching for therapeutics that mimic the life-extending benefits of caloric restriction, exercise, and a good ...

The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...